Gabapentin Capsule
Product Images NDC 68071-2600

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68071-2600). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2600 6)

Gabapentin 100 mg capsules label by NuCare Pharmaceuticals, Inc. The label indicates a package of 60 capsules, each containing 100 mg of Gabapentin USP. Capsules are described as oblong, white, opaque with "SG" imprinted on the cap and "179" on the body. The label includes the NDC 68071-2600-6 and storage instructions to keep at controlled temperature 68-77°F. The label also states Rx Only and includes warnings to keep out of reach of children.*

FDA Label Image

Figure 1 (Image 01)

A line graph comparing mean pain scores over 8 weeks for placebo and Gabapentin 3600 mg/day groups. The graph shows a 4-week dose titration period followed by a 4-week fixed dose period. Pain scores for the gabapentin group decrease steadily over time, while placebo scores remain relatively stable.*

FDA Label Image

Figure 2 (Image 02)

A line graph depicting mean pain scores over seven weeks for three groups: placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks, including a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Both Gabapentin groups show a greater reduction in pain scores compared to placebo over time.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing data from two studies. The y-axis displays percentages from 0% to 100%, and bars represent response rates for placebo (PBO) and gabapentin (GBP) at different dosages (3600 mg in Study 1; 1800 mg and 2400 mg in Study 2). Statistical significance indicators are noted with asterisks for comparisons to placebo.*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

A formula for calculating creatinine clearance (CLCr) based on age, weight, and serum creatinine levels, including an adjustment factor for female patients.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of the active ingredient gabapentin, showing its molecular arrangement with a cyclohexane ring and attached amino and carboxyl groups.*

FDA Label Image

Image-09 (Image 09)

A scatter plot chart showing percentage difference on the vertical axis and daily dose in milligrams (600, 900, 1200, 1800 mg) on the horizontal axis. It compares data points from three studies labeled 'STUDY a,' 'STUDY b,' and 'STUDY c,' represented by black, gray, and white squares respectively, illustrating differences across daily doses for Gabapentin capsules.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.